Knockdown of FYN kinase by pharmacological inhibition or siRNA-mediated re-sensitization of chronic granulocytic leukemia (CML) cells to the BCR-ABL inhibitor imatinib-resistant cell line (IM-R cells) to imatinib [135]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.